pH-sensitive niosomes: effects on cytotoxicity and on inflammation and pain in murine models by Rinaldi, Federica et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ienz20
Download by: [Universita Studi la Sapienza] Date: 29 March 2017, At: 03:23
Journal of Enzyme Inhibition and Medicinal Chemistry
ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: http://www.tandfonline.com/loi/ienz20
pH-sensitive niosomes: Effects on cytotoxicity and
on inflammation and pain in murine models
Federica Rinaldi, Elena Del Favero, Valeria Rondelli, Stefano Pieretti, Alessia
Bogni, Jessica Ponti, François Rossi, Luisa Di Marzio, Donatella Paolino,
Carlotta Marianecci & Maria Carafa
To cite this article: Federica Rinaldi, Elena Del Favero, Valeria Rondelli, Stefano Pieretti, Alessia
Bogni, Jessica Ponti, François Rossi, Luisa Di Marzio, Donatella Paolino, Carlotta Marianecci &
Maria Carafa (2017) pH-sensitive niosomes: Effects on cytotoxicity and on inflammation and pain
in murine models, Journal of Enzyme Inhibition and Medicinal Chemistry, 32:1, 538-546, DOI:
10.1080/14756366.2016.1268607
To link to this article:  http://dx.doi.org/10.1080/14756366.2016.1268607
© 2017 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 23 Jan 2017. Submit your article to this journal 
Article views: 123 View related articles 
View Crossmark data
RESEARCH ARTICLE
pH-sensitive niosomes: Effects on cytotoxicity and on inflammation and pain
in murine models
Federica Rinaldia, Elena Del Faverob, Valeria Rondellib, Stefano Pierettic, Alessia Bognid, Jessica Pontid,
Franc¸ois Rossid, Luisa Di Marzioe, Donatella Paolinof,g, Carlotta Marianeccih and Maria Carafah
aFondazione Istituto Italiano di Tecnologia, Center for Life Nano Science@Sapienza, Rome, Italy; bDepartment of Medical Biotechnologies and
Traslational Medicine, University of Milan, Milan, Italy; cDepartment of Therapeutic Research and Medicine Evaluation, Istituto Superiore di
Sanita, Rome, Italy; dConsumers and Reference Materials, Consumer Products Safety Unit (F.2), European Commission, Directorate General Joint
Research Centre Directorate F – Health, ISPRA, Varese, Italy; eDepartment of Pharmacy, University “G. d’Annunzio”, Chieti, Italy; fInterregional
Research Center for Food Safety & Health (IRC-FSH), Campus Universitario “S. Venuta”, University of Catanzaro “Magna Græcia”, Catanzaro, Italy;
gDepartment of Health Sciences, Campus Universitario “S. Venuta”, University of Catanzaro “Magna Græcia”, Catanzaro, Italy; hDepartment of
Drug Chemistry and Technology, University of Rome “Sapienza”, Rome, Italy
ABSTRACT
pH-sensitive nonionic surfactant vesicles (niosomes) by polysorbate-20 (Tween-20) or polysorbate-20 deriv-
atized by glycine (added as pH sensitive agent), were developed to deliver Ibuprofen (IBU) and Lidocaine
(LID). For the physical-chemical characterization of vesicles (mean size, size distribution, zeta potential, ves-
icle morphology, bilayer properties and stability) dynamic light scattering (DLS), small angle X-ray scatter-
ing and fluorescence studies were performed. Potential cytotoxicity was evaluated on immortalized human
keratinocyte cells (HaCaT) and on immortalized mouse fibroblasts Balb/3T3. In vivo antinociceptive activity
(formalin test) and anti-inflammatory activity tests (paw edema induced by zymosan) in murine models
were performed on drug-loaded niosomes. pH-sensitive niosomes were stable in the presence of 0 and
10% fetal bovine serum, non-cytotoxic and able to modify IBU or LID pharmacological activity in vivo. The
synthesis of stimuli responsive surfactant, as an alternative to add pH-sensitive molecules to niosomes,
could represent a promising delivery strategy for anesthetic and anti-inflammatory drugs.
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Introduction
In several diseases and disorders, acute and chronic inflammation
is often associated with pain. Most anti-inflammatory drugs
employed for long-term administration for pain relief display
extensive adverse effects. Anesthetic and anti-inflammatory prepa-
rations show limited efficacy on intact skin and need prolonged
applications and high drug concentrations1–3. In developing top-
ical formulations, great attention has been devoted to new struc-
tures, such as vesicular nanocarriers (e.g. liposomes, niosomes,
ethosomes), allowing the localization of the drug within the skin
enhancing the local effect or increasing the penetration through
the stratum corneum.
Niosomes (NSVs) attracted great attention as nontoxic drug
delivery systems in topical/transdermal application for many rea-
sons: NSVs are effective in the modulation of drug release proper-
ties; they can act as penetration enhancers through the skin. Their
effectiveness is strongly dependent on their physical–chemical
properties, such as formulation size, surface charge and
lamellarity4–10.
In this work, niosomes based on polysorbate-20 (Tw20) or its
pH-sensitive derivative, polysorbate-20 derivatized by glycine
(TW20-GLY), were prepared to investigate the potential application
of pH responsive NSV formulation. Ibuprofen and Lidocaine
(Supplementary Figure S1) were chosen as model drugs, according
to their pharmacological activities on inflammation and pain.
Modification of pH arises in several pathological condition and
inflamed tissues often show decreased pH levels and activation of
inflammatory mediators when compared with healthy tissues11.
Nanotherapeutics with increased affinity for an acidic pH micro-
environment (i.e. 5.8–7.2) can take advantage of pathological con-
ditions of inflammation for selective targeting12. “Fusogenic”
vesicles can be also prepared: they are stable at physiological pH
(pH 7.4), but undergo destabilization under acidic conditions, lead-
ing to the release of their contents at the intracellular level or in
inflamed areas12. A novel class of compounds based on Tw20
bearing different pH sensitive head groups (i.e. glycine, N-methyl-
glycine, N,N-dimethylglycine) were synthesized by our group to
combine niosome delivery features and pH sensitivity as previously
demonstrated13.
In this study, Tween-20 and Tween-20 glycine derivatives were
mixed to obtain vesicular carriers loaded with model drugs.
Dimensions, f-potential, morphology, bilayer features, stability and
drug entrapment efficiency (EE) were evaluated in order to better
characterize the vesicles. Since the derivatives are primary amines,
they could induce toxic effects in healthy cells and tissues. Their
potential toxicity was then evaluated on immortalized human
keratinocyte cells (HaCaT) and on immortalized mouse fibroblasts
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Balb/3T3 clone A31–1-1, used as in vitro models, as alternative to
animal tests14.
Moreover, experiments to assess the in vivo efficacy of the
drug-loaded niosomes were carried out in murine models to
evaluate the potential advantages of stimuli responsive nanocar-
riers, loaded with Lidocaine or Ibuprofen in pain and inflammation
treatments.
Materials and methods
Materials
Tween-20 (Tw20), Sephadex G-75, Hepes salt [N-(2-hydroxyethyl)
piperazine-N-(2-ethanesulfonic acid)], calcein, Ibuprofen and
Lidocaine were purchased from Sigma-Aldrich (Sigma-Aldrich SRL,
Milan, Italy). Cholesterol (CHOL) and diphenylhexatriene (DPH)
were obtained from Acros Organics (Acros Organics BVBA, Geel,
Belgium). All other products and reagents were of analytical grade.
Tween-20 derivative was synthesized as previously described:
briefly, terminal hydroxyl groups were functionalized with glycine
(GLY) following the Eschweiler–Clarke reaction13,15.
Vesicle preparation and purification
Surfactant vesicles (NSVs) were prepared using Tween-20 or
Tween-20 glycine derivative and CHOL as reported in Table 1.
Where indicated, the fluorescent probe DPH (2 103 M) or the
drugs (Table 1) were added to the surfactant/CHOL mixture before
the solubilization in the organic phase. The vesicles were obtained
by the “film” method as previously described (see Supplementary
data available online)16–18. Vesicle dispersions were purified by
size exclusion chromatography on Sephadex G-75 glass columns.
Size and f-potential measurements of vesicles
Dynamic light scattering (DLS) on a Malvern Zetasizer Nano ZS90
(Malvern Instruments Ltd, Worcestershire, UK) was applied to
evaluate the size and the f-potential of the NVS dispersions.
Reported data represent mean of the f-potential (mV) and of the
hydrodynamic diameter (nm). NSV samples were diluted 1:100 in
HEPES buffer (10mM, pH7.4) or acetate buffer (200mM, pH 5.5).
The measurement of the breadth of the size distribution (polydis-
persity index, PDI) value was also evaluated.
Synchrotron small angle X-ray scattering measurements
SAXS measurements were performed at ESRF (Grenoble, France)
on ID02 high-brilliance beamline (k¼ 0.1 nm). Samples were put
into capillaries (KI-beam; ENKI, Concesio, Italy) and mounted hori-
zontally onto a six-places sample holder, allowing for nearly con-
temporary measurements on sample and reference cells in the
same environmental conditions. All measurements were performed
at 25 C. The exposure time of each measurement was very short,
0.1 s, in order to avoid any radiation damage. The scattered inten-
sity at different angles was collected on a 2D detector and ana-
lyzed. The SAXS intensity profiles report the scattered radiation
intensity as a function of the momentum transfer q, proportional
to the scattering angle, in the region 0.02 nm1q 3.5 nm1. To
investigate a wide q-region, spectra relative to different q ranges
were compared and joined after careful background subtraction.
Analysis was carried out to obtain information on size and shape
of the particles in solution. The features of the large-scale struc-
ture, corresponding to the overall particle, are displayed in the
very-low q-region (q< 0.1 nm1), while the ones of the internal
structure can be identified for q> 0.1 nm1.
Vesicle fluidity determination
DPH was added to vesicle composition at 2 103 M. DPH-labeled
vesicles were prepared as reported above. To avoid any experimen-
tal artifact, i.e. to allow the fluorescent probe disposition in the ves-
icle bilayer, samples were stored 3 h at room temperature before
the fluorescence anisotropy experiments. The fluidity of surfactant
vesicular membranes was determined by fluorescence anisotropy
using DPH as fluorescence probe, as previously reported18.
Determination of drug EE
Drug entrapment within nonionic surfactant vesicles was deter-
mined using high-performance liquid chromatography (HPLC), as
previously described, on purified NVS after disruption with isopro-
panol (vesicle dispersion/isopropanol 1:1 v/v final ratio)6,19.
Drug EE was calculated as follows:
E:E ¼ DrugEnt
DrugTot
 100
Results are the average of three different batches ± standard
deviation.
Vesicle stability evaluation
For colloidal stability at different temperatures, the vesicle formu-
lations were stored at 4 and 25 C for a period of 90 days.
Samples from each batch were withdrawn at definite time inter-
vals (1, 30, 60 and 90 days) and the f-potential and the mean of
hydrodynamic diameter of vesicles were determined as previously
described.
To study the effect of fetal bovine serum (FBS) on vesicle stabil-
ity calcein-loaded vesicle suspensions (250 lL) were added to
2.25mL buffer solution in absence (0% FBS) or in presence of 10%
of FBS20,21.
Calcein leakage was evaluated after 3 h and compared to cal-
cein fluorescence intensity (Ex/Em 492/520 nm) after complete
leakage by addition of isopropanol (1/1 v/v), detected by means
of a Perkin-Elmer LS50B spectrofluorometer (Perkin-Elmer,
Waltham, MA). Vesicle size determinations were also performed
after incubation. The effect of cell culture medium on vesicle sta-
bility was also evaluated on calcein-loaded samples.
Table 1. Sample composition (in bold: selected formulations).
Sample
TW20
(mM)
TW20-GLY
(mM)
CHOL
(mM)
IBU
(%p/v)
LIDO
(%p/v)
TW20 15 – 15 – –
TW20 1% IBU 15 – 15 1 –
TW20 3% IBU 15 – 15 3 –
TW20 5% IBU 15 – 15 5 –
TW20 7% IBU 15 – 15 7 –
TW20 1% LID 15 – 15 – 1
TW20 3% LID 15 – 15 – 3
TW20 5% LID 15 – 15 – 5
TW20 7% LID 15 – 15 – 7
TW20-GLY 3.75 11.25 7.5 – –
TW20-GLY 1% IBU 3.75 11.25 7.5 1 –
TW20-GLY 3% IBU 3.75 11.25 7.5 3 –
TW20-GLY 5% IBU 3.75 11.25 7.5 5 –
TW20-GLY 7% IBU 3.75 11.25 7.5 7 –
TW2OGLY 1% LID 3.75 11.25 7.5 – 1
TW20-GLY 3% LID 3.75 11.25 7.5 – 3
TW20-GLY 5% LID 3.75 11.25 7.5 – 5
TW20-GLY 7% LID 3.75 11.25 7.5 – 7
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Cytotoxicity studies
Cytotoxicity of the vesicles was studied in two different cell lines:
immortalized HaCaT cells and immortalized mouse fibroblasts
Balb/3T3 clone A31–1-1, using the in vitro colony-forming effi-
ciency assay (CFE)22.
Cell culture conditions
HaCaT cells were originally supplied by the German Cancer
Research Center (Heidelberg, Germany) and Balb/3T3 clone
A31–1-1 was purchased from Hatano Research Institute
(Kanagawa, Japan).
Experimental cultures were prepared from deep-frozen stock
vials always maintained in a sub-confluent state (maximum
60–70% confluence) in complete culture medium. HaCaT cells
were cultured in DMEM high glucose (Invitrogen, Milan, Italy) sup-
plemented with 10% (v/v) Fetal Clone II serum (Hyclone, Celbio,
Italy) and 0.6% (v/v) penicillin/streptomycin (Invitrogen). Balb/3T3
cells were cultured in minimum essential medium (MEM) low glu-
cose supplemented with 10% (v/v) FBS and 0.6% (v/v) penicillin/
streptomycin (Invitrogen, Italy). All the cell cultures were main-
tained in standard cell culture conditions (37 C, 5% CO2 and 95%
humidity, HERAEUS Incubator, Hanau, Germany).
CFE assay Both cell lines were seeded on 60 15mm Petri dishes
(19.3 cm2 bottom surface area, Corning, Costar, Italy) at a density
of 200 cells/dish in 2mL complete culture medium in three repli-
cates for each treatment condition. After 24 h, the vesicles formu-
lations were directly added to the cell culture to obtain the
appropriate final concentrations of 0.1, 0.5, 1, 5, 10, 50 and
100 lg/mL. As a control, the surfactants in non-vesicular formula-
tion were tested at the same concentration range as the vesicular
formulation. After 2 or 4 h of exposure for HaCaT and 2 or 24 h of
exposure for Balb 3T3, the treatment medium was removed and
changed with complete fresh culture medium that was renewed
twice a week. After 7 days, cells were fixed for 20min with 3.7%
(v/v) formaldehyde solution (Sigma, Milan, Italy) in phosphate-buf-
fered solution (PBS) (1, GIBCO, Monza, Italy) and stained for
30min with 4% (v/v) Giemsa solution (GS-500; Sigma, Milano, Italy)
in ultrapure water. Colonies were automatically scored using
Gelcount colony counter (Oxford Optronix, Oxford, UK). Each
experiment included a negative control (untreated cells in culture
medium), a positive control (cells exposed to sodium chromate
100 lM, CAS No. 10034-82-9 Sigma) and a PBS solvent control
(cells exposed to the same solvent contained in the stock of nio-
somes suspension). The results were normalized to the solvent
control and expressed as CFE (%) (average number of colonies in
treatment/average number of colonies in solvent control,100).
In vitro release
In vitro release experiments were performed in a flow-through
apparatus (EP) at 32 C in a pH 5.5 buffer. Fixed volumes of vesicle
samples were included in dialysis sacs (cut-off 8.000) with a fixed
diffusing area (5.5 cm2). The drug concentration was detected in
the outer solution at fixed time intervals by means of the HPLC
method described above, taking into account the dilution factor.
In vivo experiments
The following experiments were approved by the Service for
Biotechnology and Animal Welfare of the Istituto Superiore di Sanita
and authorized by the Italian Ministry of Health, according to
Legislative Decree 26/2014, which implemented the European
Directive 2010/63/UE on laboratory animal protection in Italy.
Animal welfare was routinely checked by veterinarians from the
Service for Biotechnology and Animal Welfare of the Istituto
Superiore di Sanita. TW20 and TW20-GLY loaded with LID or IBU,
diluted to obtain the same drug concentration, were compared to:
(i) the “unstructured” surfactant formulation and (ii) the
“unstructured” surfactant formulation with the same IBU or LID
concentration.
Animals, male CD-1 mice (Harlan, Italy) weighing 25–30 g were
used for all experiments. Mice were housed for at least 1 week
before the experimental sessions in colony cages (seven mice in
each cage) under standard light (from 7.00 a.m. to 7.00 p.m.), tem-
perature (21 ± 1 C), relative humidity (60 ± 10%) with food and
water available ad libitum.
Formalin test
Subcutaneous injection of a dilute solution of formalin (1%,
20 lL/paw) into the mice hind paw evokes nociceptive behavioral
responses, such as licking, biting the injected paw or both, which
are considered indices of nociception. The nociceptive response
shows a biphasic trend, consisting of an early phase occurring
from 0 to 10min after the formalin injection, due to the direct
stimulation of peripheral nociceptors, followed by a late prolonged
phase occurring from 15 to 40min, that reflects the response to
inflammatory pain. The total time (s) that the animal spent licking
or biting its paw during the formalin-induced early and late phase
of nociception was recorded23. Samples were administered sub-
cutaneously in the dorsal surface of mice paw 120min before for-
malin in a volume of 40lL/paw.
Zymosan-induced paw edema
Mice received a subcutaneous administration (20 lL/paw) of zymo-
san (2.5% w:v in saline) into the dorsal surface of the right hind
paw24. Paw volume was measured three times before the injec-
tions and at 1, 2, 3, 4, 24 and 48 h thereafter using a hydroplethys-
mometer modified for small volumes (Ugo Basile, Varese, Italy).
Samples were administered subcutaneously in the dorsal surface
of mice paw 120min before zymosan in a volume of 40lL/paw.
The increase in paw volume was evaluated as percentage differ-
ence between the paw volume at each time point and the basal
paw volume.
Data analysis and statistics
The statistically significant differences for CFE values versus con-
trols were calculated by the one-way analysis of variance (ANOVA)
analysis (GraphPad Prism 4 statistical software, GraphPad Inc., San
Diego, CA). Differences were considered statistically significant
when p< 0.05. Data are presented as average of three independ-
ent experiments.
Experimental data from in vivo experiments were expressed as
mean± standard error of mean and the significance among the
groups was evaluated with the analysis of variance followed by
Tukey’s post-hoc comparisons using GraphPad Prism 6.03 software.
Statistical significance was assumed at least for p< 0.05.
Results
Vesicular nanocarrier characterization
The measurements carried out by DLS indicate that vesicular struc-
tures with significantly different sizes were obtained, according to
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surfactant mixture and drug loaded in NSVs. The interaction of
both drugs with Tw20 and TW20-GLY vesicles led to a decrease in
vesicle dimensions, when compared to empty ones, without modi-
fication of the corresponding f-potential values (Table 2).
Furthermore, Tw20- and TW20-GLY-based systems were investi-
gated by Small Angle X-ray scattering to obtain information on
the effect of Ibuprofen or Lidocaine loading on the size and shape
of the aggregates and on their internal structure.
Figure 1 reports SAXS intensity spectra for Tw20- and TW20-
GLY-based systems, at pH 7.4, vertically shifted for enhanced visi-
bility. Spectra display some common features and some peculiar-
ities in all the q range. Analysis of the intensity profiles shows that
all Tw20- and TW20-GLY-based systems aggregate in solution as
vesicles.
Loaded vesicles are smaller in size (100 nm) in both cases, in
accordance to what observed by DLS. Actually, the inclusion of
drugs in Tw20 and TW20-GLY vesicles led to an increase in fluores-
cence anisotropy, this related to a decrease in bilayer fluidity
(Table 2). Furthermore, a higher E.E. was observed in Lidocaine-
loaded samples when compared to Ibuprofen-loaded ones
(Table 2)
Lidocaine, embedded in the bilayer, gives a higher spontan-
eous curvature to the aggregate. In the Tween20-based system
(see orange points, left panel, Figure 1), this behavior results in
quite monodisperse round shaped vesicles. The characteristic SAXS
intensity profile has been reproduced, as reported in
Supplementary Figure S2, with the form factor of a spherical hol-
low particle (external radius 46 nm) with a shell constituted by a
bilayer with thickness of 6 nm. In the TW20-GLY system, the SAXS
intensity profile of loaded niosomes (orange points, right panel,
Figure 1) displays a different behavior, with both a shift and a par-
tial filling of the first intensity minimum. On the local scale, all
vesicles are constituted by a single bilayer, as visible in Figure 1
from the typical q2 behavior of the intensity profile. The trans-
verse structure of the bilayers affects the high q-region of the
intensity spectra. In the case of TW20-GLY vesicles, the high
q-region of the intensity profile (q> 0.4 nm1) is altered by the
presence of Ibuprofen.
Unloaded vesicles are stable for at least 6 months when stored
at 4 C and at least 3 months when stored at 25 C (data not
shown). Drug-loaded samples, in spite of the decrease in bilayer
fluidity, are stable only for 1 month when stored at 25 C (data
not shown). Difference in bilayer fluidity does not affect vesicle
stability, whereas drug release is affected by this parameter
(Figure 2(A,B)): TW20-GLY samples (Figure 2(B)), with high bilayer
fluidity, show higher drug release compared to Tween-20 samples
(Figure 2(A)).
To better simulate in vivo conditions, all tested samples were
analyzed at pH 7.4 in the presence of 0 and 10% FBS. The addition
of serum to surfactant vesicular formulations at pH 7.4 did not
modify significantly the vesicle stability (i.e. the percentage of cal-
cein released after 3 h, for further details see Supplementary
Figure S3).
CFE
Changes in cell viability of Balb/3T3 and HaCaT cells, after expos-
ure to Tw20 and TW20-GLY formulations at concentrations ranging
from 0.10 to 100 lM, were evaluated by the CFE assay. The Balb/
3T3 cells were treated with Tw20 and TW20-GLY formulations,
Tween-20 control and Tween-20 glycine control (material not in
vesicular form) for 2 and 24 h and HaCaT cells for 2 and 4 h.
Results are expressed as percentage of CFE versus the solvent con-
trol and they are average of three independent experiments, with
three replicates for each experimental point (Figures 3 and 4). The
solvent control (PBS at the same concentration used for analyzed
formulation) did not induce any cytotoxicity compared to the
negative control. Treatment with the positive control resulted in
complete cell death, as expected (data not shown).
Balb/3T3 cells incubated with Tw20 formulation and with
Tween-20 control for 2 h (Figure 3(A)) show no statistically
Table 2. Sample characterization.
Sample Size (nm) Potential, f (mV) PDI Fluorescence anisotropy EE (mg/ml)
TW20 140.8 ± 1.6 30.4 ± 1.0 0.219 ± 0.04 0.21 ± 0.01 –
TW20 5% IBU 90.6 ± 1.8 31.7 ± 0.3 0.306 ± 0.09 0.30 ± 0.02 0.28 ± 0.04
TW20 5% LIDO 99.3 ± 1.8 28.9 ± 0.1 0.133 ± 0.09 0.29 ± 0.01 7.00 ± 0.03
TW20-GLY 215.0 ± 3.0 41.0 ± 1.2 0.160 ± 0.08 0.17 ± 0.01 –
TW20-GLY IBU 5% 122.1 ± 19.6 40.2 ± 0.1 0.404 ± 0.05 0.20 ± 0.04 0.18 ± 0.05
TW20-GLY LIDO 5% 121.0 ± 2.3 42.8 ± 1.3 0.203 ± 0.02 0.23 ± 0.02 8.65 ± 0.04
Figure 1. SAXS intensity spectra for Tw20 (left panel) and TW20-GLY (right panel) based systems, at pH 7.4, vertically shifted for enhanced visibility. From bottom to
top: unloaded (black), loaded with 5% ibuprofen, loaded with 5% lidocaine. Dash lines decrease with q2 behavior, typical for bilayer structures.
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significant cytotoxicity at all concentrations tested. After 24 h of
incubation (Figure 3(B)), statistically significant cytotoxicity was
found in Balb/3T3 cells exposed to Tween-20 control at 50 and
100 lM (p< 0.0001) but not to the Tw20 formulations at the
same concentrations. The calculated IC50 for Tween-20 control and
Tw20 formulations after 24 h of incubation, are respectively of
64.8 ± 5.5 and 25.3 ± 13.2 lM (Hill’s Function, Graph Pad Prism).
IC50 for Tw20 and for Tween-20 control after 4 h of incubation is
higher than 100 lM (maximum concentration tested).
Balb/3T3 cells incubated with TW20-GLY formulation and with
Tween 20 glycine control for 2 h (Figure 3(C)) show no statistically
significant cytotoxicity at all tested concentrations. After 24 h of
incubation (Figure 3(D)), statistically significant cytotoxicity was
found in Balb/3T3 cells exposed to TW20-GLY formulation at
50 lM (p< 0.001) and 100 lM (p< 0.0001) and to Tween-20
glycine control at 100 lM (p< 0.001). At 24 h incubation, the
IC50 of TW20-GLY formulations is of 25.8 ± 8.3lM and the IC50 of
Tween-20 glycine control is of 61.7 ± 2 lg/mL. IC50 for TW20-GLY
Figure 2. Release profiles of IBU and LID from the vesicular carriers in HEPES (pH ¼7.4) at 32 C as a function of time: (A) TW20 samples; (B) TW2–0GLY samples.
Release experiments were carried out in triplicate. The reported value represents mean values and lay within 10% of the mean.
Figure 3. Cytotoxic effects of TW20 and TW20-GLY on Balb-3T3 cells as evaluated by CFE assay. Cells were exposed to increasing concentrations (0.1–100lM) of Tw20
formulation and to the same concentration of Tween 20 control for 2 h (A) and 24 h (B) and to increasing concentrations (0.1–100lM) of TW20GLY formulation and of
Tween-20 glycine control not in vesicular form for 2 h (C) and for 24 h (d). In this range of concentrations, statistically significant cytotoxicity was found in Balb/3T3 cells
exposed for 24 h to Tween-20 control at 50lM and 100lM (p< 0.0001) but not to the Tw20 vesicles at the same concentrations. Statistically significant cytotoxicity
was also found in cells exposed to Tw20GLY formulation at 50lM (p< 0.001) and 100lM (p< 0.0001) but not to the Tween-20 glycine control at the same
concentrations.
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and Tween-20 glycine control after 4 h of incubation, is higher
than 100 lM. Both Tw20 and TW20-GLY formulations started to
show a dose effect relationship at 24 h of incubation.
HaCaT cells exposed for 2 h to Tw20 formulation and Tween-20
control (Figure 4(A)) and to TW20-GLY formulation and Tween-20
glycine control (Figure 4(B)) show no cytotoxicity at all tested con-
centrations. After 4 h of incubation with TW20-GLY vesicles and
Tween-20 glycine control (Figure 4(C)) no cytotoxicity was
observed (IC50 is higher than the tested concentration). The 4 h
exposure to Tw20 formulation shows a statistically significant cyto-
toxic effect at 50 and 100 lM (p< 0.001), while no cytotoxicity
was observed for the Tween-20 control at the same concentra-
tions. The calculated IC50 for Tw20 formulation is 32.9 ± 9.2lM, for
the Tween-20 control is higher than 100 lM and 100lg/mL,
respectively.
In vivo experiments
The results obtained in the formalin test are reported in Figure
5(A,B). The administration of the surfactant solution (V) did not
change the response to formalin both in the early and in the late
phase of the test. When IBU or LID were administered together
with TW20 empty vesicles or loaded in TW20 vesicles in the mice
paw before formalin we did not observe any differences in the
paw licking induced by formaldehyde. On the contrary, pH-sensi-
tive vesicles loaded with IBU or LID were able to strongly reduce
licking activity induced by formalin in both test phases. The effects
of IBU loaded vesicles on edema development induced by zymo-
san are reported in Figure 6. The administration of vesicles alone,
IBU and TW20 vesicles or IBU in TW20 vesicles did not change
paw edema increase. When IBU loaded pH-sensitive vesicles were
administered before zymosan, a significant reduction in paw
volume development was recorded. The reduction in paw volume
increase started 1 h after zymosan administration and was still pre-
sent 24 h thereafter.
Discussion
The surfactant vesicles, prepared with the mixture of surfactants,
CHOL and drugs at different molar ratio (Table 1), showed size
and f-potential values not always useful for proposed in vivo
application (data not shown); for this reason only the results on
samples with higher EE (Table 2) are reported and discussed.
Tw20 and TW20-GLY based systems were investigated by small
angle X-ray scattering to obtain information on the effect of
Ibuprofen or Lidocaine on vesicle features. SAXS data are in good
agreement with DLS results: vesicle sizes are quite different for the
different systems, being larger for the TW20-GLY unloaded vesicles
(215 nm) with respect to the Tw20 ones (140 nm). Taking into con-
sideration the derivatization of PEG chains, it can be assumed that
the reported data may be connected to differences in the solv-
ation state of PEG polymeric chains25.
Loaded vesicles, maintaining the single bilayer structure, are
smaller in size (100 nm) in both cases, in accordance to what
observed by DLS; this is reasonably related to an higher spon-
taneous curvature due to the partial inclusion of amphiphilic
drugs in vesicle bilayer, leading to a decrease in their bilayer
fluidity.
The slighter decrease in vesicle bilayer fluidity of TW20-GLY
samples (Table 2) could be related to a partial “partition” of the
drug between hydrophobic and hydrophilic regions. SAXS results
on the local structure of TW20-GLY bilayer could confirm that the
presence of Ibuprofen within the bilayer affects not only the
hydrophobic core, but also its hydrophilic regions.
Figure 4. Cytotoxic effects of TW20 and TW-20GLY on HaCaT cells evaluated by CFE assay. HaCaT cells were exposed to increasing concentration of TW20 formulation
and to the same concentration of Tween-20 control for 2 h (A) and 4 h (B) and to increasing concentrations (0.1–100lM) of TW20-GLY formulation and of Tween-20
glycine control for 2 h (C) and for 24 h (d). In this range of concentrations, statistically significant cytotoxicity was observed only in HaCat cells exposed to TW20 formu-
lation at 50 and 100lM (p< 0.001).
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Lidocaine higher EE in Tw20 and TW20-GLY samples is in
agreement with the Lidocaine molecule interaction with the
hydrophobic moiety of Tweens previously reported26,27. Reduced
Ibuprofen drug loading could be related to electrostatic repulsive
forces between the carboxyl group of Ibuprofen and the polar nio-
some surface (Table 2)28.
Actually, Lidocaine, entrapped in both vesicular structures in
higher amount than Ibuprofen, seems to display a larger effect on
vesicles size and shape: SAXS results indicate a change of the nio-
somes form factor from spherical vesicles to elongated, ellipsoidal
vesicles, induced by the presence of Lidocaine within the closed
bilayer. The potential in vivo use of vesicle formulations is also
related to their stability at different storage temperature and in
the presence of 0 and 10% FBS29.
Decreased drug-loaded vesicle stability when stored at 25 C
(1 month) could be affected by the decrease of vesicle size leading
to an increase of the interfacial curvature free energy30. On the
other hand, the addition of serum at pH 7.4 did not modify signifi-
cantly the vesicle stability (Figure 4).
Since TW20-GLY is a primary amine, potentially toxic in healthy
cells and tissues, cytotoxicity was evaluated on HaCaT and Balb/
3T3 clone A31–1-1 cells. The obtained results show that the nio-
somes are not toxic to the cells: they only show toxicity at high
concentration and for prolonged exposure (Figures 5 and 6).
In order to choose the better formulation to be tested in
in vivo experiments, release studies were carried out. TW20-GLY
samples (Figure 3(B)), with high bilayer fluidity, show higher drug
release compared to Tween-20 samples (Figure 3(A)), this being
probably related to drug diffusion through vesicle bilayer rather
than to vesicle disruption. The lipid composition of vesicles can
influence the entrapment and the release of sparingly soluble
drugs with a general correlation between release rates and bilayer
fluidity of vesicle bilayer with decreased release rate with limited
bilayer fluidity28,31. The presence of cholesterol induces membrane
stability via an interaction between the rigid hydrophobic ring
structure of the molecule and the alkyl side-chains of amphiphilic
molecules, which ultimately decreases membrane fluidity32. It can
be assumed that cholesterol hinders the drug incorporation within
the bilayer because of its bulky nature. This effect is less evident
in TW20-GLY samples, incorporating a lower amount of cholesterol
as compared to TW20 samples (Table 1). Self-assembly is at the
basis of niosomes formation. The final structure of the niosome
results from the interplay among all the different molecules pack-
ing requirements, their lateral distribution within each layer
(internal and external) and their asymmetric disposition within the
two layers.
In both systems, the presence of drug induces a marked reduc-
tion in size of the vesicles, corresponding to an increase in the
spontaneous curvature. Loaded bilayers can close in smaller, highly
curved particles, thanks to the presence within the bilayer of an
additional component, the drug, that can be distributed non-
uniformly both laterally and transversely inside the hydrophobic
core. Moreover, in TW20 and TW20-GLY, self-assembled niosomes
cholesterol can be partially excluded from the bilayer or can be pre-
sent in the form of crystallites33,34. The presence of an additional
amphiphilic component may change the amount and the distribu-
tion of cholesterol within the two leaflets of the bilayers.
The best behavior in “in vitro” release experiments of pH-sensi-
tive vesicles (samples TW20-GLY 5% LIDO and TW20-GLY 5% IBU,
Table 1) was confirmed in “in vivo” experiments in murine models
highlighting the potential advantages of stimuli responsive nano-
carriers in pain and inflammation treatments. Niosomes containing
pH-sensitive components, such as TW20-GLY that protonate at
lower pH, show a destabilization of the carrier bilayer, probably
due to the segregation or leakage of cholesterol33.
The increased fluidity of the bilayer allows a higher in vitro
drug release if compared to Tween-20 samples (Figure 3) and an
enhanced therapeutic effects in in vivo pain and inflammation
models.
Conclusion
Many different interactions are present in complex structures, such
as pharmaceutical formulations. The “deconstruction” of the
Figure 5. In vivo effects of drug-loaded nonionic surfactant vesicles on formalin-induced nociception (IBU: panel A; LID: panel B). Purified formulation of vesicles and
drug solution at the same drug concentration were used. The data are considered to be statistically significant for Pb0.05, Pb0.01 and Pb0.001 versus vehicle-
treated animals (HEPES buffer). N¼ 9–10.
Figure 6. In vivo effects of drug-loaded vesicles in edema induced by zymosan.
Purified formulation of vesicle and drug solution at the same drug concentration
were used. The data are considered to be statistically significant for Pb0.05,Pb0.01 and Pb0.001 versus vehicle-treated animals (HEPES buffer).
N¼ 10–12.
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carriers may be a crucial step to engineer novel ways to deliver
drugs and represents the crossroad of an interdisciplinary effort to
develop strategies to combat different diseases.
An essential tool in the pharmaceutical application of vesicular
carriers as delivery systems for drugs is their efficient and stable
encapsulation of such drugs. In the present work, we have shown
that niosomes could be prepared to entrap drugs with different
stability and release characteristics, with the drug entrapment cap-
acity being dependent on the surfactant used and the physical-
chemical characteristics of the drug.
The TW20 and TW20-GLY niosomes formulations are stable and
nontoxic and were tailored for the optimization of their pharma-
ceutical properties, such as drug release rate and in vivo anti-noci-
ceptive and anti-inflammatory activity. In vivo tests of TW20-GLY
loaded with IBU and LID show the efficiency of the drug delivery
as compared to the free active principle, therefore confirming the
interest of the pH-sensitive nanocarrier formulation.
Thus, the synthesis of novel stimuli responsive surfactant, as an
alternative to add pH-sensitive molecules to niosome formulation,
represents an effective and promising delivery strategy, which
may greatly increase the utility of niosomes as a targeted delivery
vehicle which is degraded only in the target area, where the drug
will be released and accumulated. On the other hand, the carrier
can be evenly distributed within the circulation since at physio-
logical pH the TW20-GLY niosomes have chemical–physical proper-
ties, that will promote their half time of circulation and hence
biodistribution by avoiding their capture by reticuloendothelial
system, due to the presence of PEG chains on the polar head
group of TW20.
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